Rates of osteoporosis and fracture may be increased in HIV but there are few UK data. Our aim was to examine the prevalence of and risk factors for osteoporosis and fractures among a homogeneous cohort of well-characterized HIVinfected men. In total, 168 men were recruited, median age 45 years, 37 combination antiretroviral therapy (cART) naïve, 46 with <3 years cART exposure and 85 cART-exposed longer term (median >10 years). All participants provided information on bone health and underwent DEXA scanning. Osteopenia was found in 58% of subjects and osteoporosis in 12%; 14% reported fractures since HIV diagnosis. Number of fractures since HIV diagnosis was significantly increased among those with osteoporosis (OR 3.5, 95% CI 1.2-10.4, p ¼ 0.018). Duration of infection greater than 13 years was significantly associated with osteoporosis. Duration of cART was associated in univariate but not multivariate analyses. Strategies to prevent osteoporosis and fractures in HIV will require attention to viral and lifestyle factors and not just cART.
Introduction
Osteoporosis is a systemic skeletal disorder characterized by low bone mass and predisposition to fracture. 1 Osteoporotic fractures increase in frequency with age, occur after low trauma (typically a fall from standing height or less) and affect sites of predominantly trabecular bone, particularly the vertebrae, distal radius and hip, although fractures at other sites e.g. pelvis are also caused by osteoporosis. 2 Osteoporotic fractures are devastating: for example, rates of mortality are 36% for men and 21% for women in the year after hip fracture and 50% of survivors lose the ability to live independently. 3 Costing an estimated 1.7 billion 4 annually in the UK, osteoporosis is a condition for which prevention rather than cure is desirable.
In the era of near-normal life expectancy achieved with combination antiretroviral therapy (cART), osteoporosis is increasingly recognised as an important non-AIDS morbidity. 5 In a meta-analysis of available casecontrol studies, a 3.7-fold increased risk of osteoporosis and a 6.4-fold increased risk of osteopenia were estimated among HIV cases as compared with noninfected controls and protease inhibitors (PIs) were implicated as an important risk factor. 6 Data on prevalence of low bone mineral density (BMD) in the UK HIV-infected population are sparse. To date, two studies have shown a prevalence rate of low BMD of 56À71%. 7, 8 A criticism of published studies is that the classification criteria for low BMD varies, with some investigators applying WHO T-scores to all subjects, including those aged <50 years (amongst whom WHO T-scores are not validated) and thus result in an overestimate of the prevalence of low BMD. 9, 10 Although there are data to suggest that HIV-infected adults have increased rates of osteoporosis compared with controls, the question remains as to whether this translates into an increased fracture risk, 5 not least because the majority of fragility fractures occur later in life. There are some data suggesting increased rates of fracture among HIV-infected cohorts, [11] [12] [13] [14] [15] [16] but few published studies of fracture in HIV have also included assessment of BMD. In one such study, similar rates of fracture were found among cases as among controls despite a higher prevalence of low BMD among cases. 16 In the cohort studies of HIV and fracture without BMD, some found that an excess of traditional osteoporosis risk factors explained the increase in fracture incidence, 13 but others found that HIV-associated factors such as stage of infection, low CD4 counts and co-infection with hepatitis C were associated with increased fracture risk. 14, 15 Male osteoporosis has been under-researched. In the UK, the lifetime risk of a fragility fracture for a man aged 50 years is estimated at 20.7%, a risk similar to that of myocardial infarction and exceeding that of lung and prostate cancer combined. 17 Amongst men, 30-60% of osteoporosis is associated with a secondary cause (glucocorticoids, excess alcohol consumption and hypogonadism). 17, 18 Hypogonadism is a recognized complication of long-term HIV infection and it may be that appropriate identification and treatment of this condition could prevent osteoporosis. 19À21 To expand the UK HIV-infected male low BMD prevalence data and examine the risk factors for low BMD, we carried out a cross-sectional study to investigate the prevalence of osteoporosis and fracture among a stable homogeneous UK cohort using ageappropriate T-and Z-scores. We investigated the associations between BMD, fracture and traditional and HIV-associated risk factors.
Methods
A cross-sectional sample of attendees at a UK Teaching Hospital HIV outpatient clinic was recruited May ÀAugust 2008. Subjects were eligible if they were male with prevalent HIV infection. Exclusion criteria: <18 years of age; unable to give written, informed consent; current participation in any other research and dual energy X-ray absorptiometry (DEXA) scan within the last 12 months. Patients were purposively sampled to represent a proportion who were cART naı¨ve; a group recently exposed for the first time to cART (<3years) and those exposed to longer term cART (>3 years).
Each subject answered a validated questionnaire including information on traditional risk factors for low BMD (smoking, alcohol and illicit drug use, exercise, family history, comorbidities, use of glucocorticoids and other drugs with bone effects) and fractures. Height and weight were measured and venous blood taken for measurement of free testosterone. Low testosterone was defined as a free serum testosterone 89 nmol/l (Elecsys 2010, Roche, Indianapolis, IN, USA). Subjects gave permission for extraction of demographic and HIV parameters, cART regimen and hepatitis B and C status from the department database. All subjects attended for DEXA scanning of the lumbar spine, total hip and femoral neck (HOLOGIC QDR 4500C, Hologic, Inc., Waltham, Massachusetts, USA). For subjects aged !50 years, WHO T-scores were generated according to subject height, weight and race. 1 For subjects aged <50 years, age-adjusted Z-scores were calculated. Using the appropriate age-defined cut-off of T<À1.0 or Z <À1.0, we estimated the prevalence of osteopenia amongst participants and using the cutoffs of T<À2.5 or Z <À2.5, we estimated the prevalence of osteoporosis.
The study was approved by the Northern and Yorkshire Research Ethics Committee, UK (Ref: 08/ H0903/13). All participants provided written, informed consent.
Data were analysed in SPSS Õ version 19 for Macintosh. Univariate associations of osteoporosis were determined using chi squared and odds ratios (OR) for categorical data and linear regression for interval data. Independent risk factors for osteoporosis were assessed using multivariate logistic regression with a backward LR method. Collinearity amongst independent variables was excluded using Pearson correlation coefficient. Differences within groups were analysed using paired T tests and ANOVA; differences between groups were analysed using independent T tests and ANOVA.
Results

Subjects
In total, 168 HIV-infected men were recruited among whom 37 were cART naı¨ve; 46 had been exposed to cART recently (<3 years) and 85 had received longer term cART (median 521 weeks). The median age of participants was 45 (IQR 38-51, range 20-85) years, 97% were Caucasian and 96% were men who have sex with men (MSM). Subjects in the naı¨ve group were significantly younger and less likely to have a diagnosis of hypogonadism than subjects treated with cART, but there were no other significant differences between groups (Table 1) . At study entry 4% of participants had a CD4 count <200 cells/mm 3 , 70% had an undetectable viral load (<40 copies) and 18% had CDC class C disease. 20 The median duration of cART was 157 weeks (IQR 4À544). In all, 27% were taking protease inhibitor (PI)-based regimens and 45% nonnucleoside reverse transcriptase (NNRTI)-based regimens; 47% of patients were taking a nucleoside reverse transcriptase inhibitor (NRTI) backbone that included tenofovir (TDF).
Site-specific prevalence of osteopenia and osteoporosis
The prevalence of osteopenia occurring in at least one of the three sites was 58% and the majority of those affected had osteopenia at the lumbar spine with/without involvement of the hip. Nobody in any of the three cART groups was found to have osteoporosis of the total hip or femoral neck, but spinal osteoporosis was found in 12% ( Table 2) . No significant differences in the prevalence of osteopenia or osteoporosis were found between cART groups.
Risk factors for osteoporosis
Traditional. Results of the univariate and multivariable logistic regression (adjusted for age and time since diagnosis) analyses of risk factors for osteoporosis are summarised in Table 3 . There was a non-significant trend for body mass index (BMI) < 18 kg/m 2 (OR 7.63, 95% CI 0.46À127.1) and hepatitis B co-infection (OR 2.3, 95% CI 0.9À6.0, p ¼ 0.076) to be associated with osteoporosis in univariate analyses. Neither hypogonadism 
History of hypogonadism (%) 0 (0) 0 (0) 10 (12) 
Total hip osteoporosis 0 (À) 0 ( À) 0 ( À) 0 ( À) Total hip osteopenia 6 (19%) 8 
Fracture since HIV diagnosis
Twenty-three (14%) subjects reported at least one fracture since HIV diagnosis. One patient reported a distal forearm fracture and one patient reported a fractured neck of femur, but there were no reported vertebral fractures. Three of the fracture subjects were cART naı¨ve; three were in the group exposed short-term (<3 years) and 17 were in the longer term cART group. . A comparison of cART class among fracture subjects showed that 46% of those with fractures since diagnosis were on PI-based regimes at the time of the study and 36% were on NNRTIbased regimes (n.s.). Seventy-seven percent of patients who reported a fracture were taking an NRTI backbone that included TDF.
Discussion
We report the results of the first UK study evaluating BMD, risk factors for osteoporosis (traditional and HIV-associated) and risk of fracture since HIV diagnosis. We have shown a prevalence of osteoporosis and osteopenia of 12% and 58%, respectively, and a 3.5fold increased risk of any fracture with osteoporosis on DEXA. We have shown that both traditional and HIV-factors were associated with the risk of osteoporosis. Modest alcohol consumption, for example, significantly attenuated the risk of osteoporosis and there was a trend for low BMI and injecting drug use to be significant risk factors. The HIV factor that was most strongly associated with osteoporosis was duration since diagnosis, with a relationship which increased with time and was most significant after 13 years. Compared with HIV duration, cART use had less effect on the risk of osteoporosis although current PI use was associated with osteoporosis in univariate analyses, but this relationship became non-significant when duration since diagnosis was added to the multivariable model. A number of studies have evaluated the prevalence of low BMD in HIV-infected cases as compared with controls, 6,7,16 but many of these studies have been criticised due to variable, if any, attention to confounding factors 9 and their heterogeneity: for example, including men with women, assessing different ethnicities using the same DEXA criteria and including subjects who acquired HIV through different transmission routes. The current study benefits from its homogeneity of gender and HIV transmission route and its rigorous attention to those factors recognised as important in male secondary osteoporosis. A strength of the current study is that transparent pre-defined criteria have been applied to the assessment of both osteoporosis and osteopenia. We have also applied transparent predefined cut-offs to the Z-scores as rigid as those applied to the T-scores in the WHO definition (i.e. <-1.0 ¼ osteopenia and <-2.5 ¼ osteoporosis). 10 In doing so, these estimates of the prevalence of low bone mass may be relative underestimates but at least are not inappropriately overestimated. It is interesting that even with our strict case definitions we found prevalence rates similar to those reported in other HIV-infected cohorts. 6, 7 Study participants reported a total of 22 fractures since diagnosis of HIV (14% of total). In the general population, fracture rates demonstrate a bimodal distribution with the first peak of fractures occurring under the age of 20 years (usually high trauma) and a second peak of fractures associated with low trauma occurring over the age of 60 years among women and 70 years among men. 22 Among men, distal forearm fractures and hip fractures are rare below 70 years. It is noteworthy that the median age of our study subjects was 45 years (IQR 38-51). Therefore, after fractures sustained in childhood and adolescence, we would expect low rates of fractures amongst a cohort of healthy men. One weakness of the study was that fracture occurrence was obtained from self-reported responses to a questionnaire. Unfortunately, many of the fractures had not occurred locally so that fractures could not be independently verified radiographically. Despite this, it is important that we have found a strong and statistically significant relationship between osteoporosis on DEXA scan and self-reported fracture since HIV diagnosis especially given that the study questionnaires were completed before the DEXA scan so that systematic recall bias was unlikely. The evidence that HIV causes increased fragility fractures is growing: Triant and colleagues 11 found increased hospitalization for fractures amongst HIV-infected patients as compared with non-infected patients in two large hospitals in one geographic location. However, in this enormous observational study, BMD could not be assessed. In fact, to date, studies of bone in HIV have usually explored either fractures or BMD but not both. 6, [11] [12] [13] [14] [15] Where both have been evaluated, findings have been contradictory. For example, Arnsten and colleagues 16 could only find a statistically significant relationship between BMD and fracture when HIV-infected cases were combined with 'at risk' HIV-uninfected controls. In their study of HIV-infected women, Prior et al. 15 showed higher rates of self-reported fracture among cases than controls, but with similar BMD at hip and lumbar spine. Although more research is required, our results suggest a strong association between fractures after diagnosis of HIV and osteoporosis on DEXA, a finding of potentially major importance to this field.
We demonstrated a significant protective effect of alcohol taken within recommended daily limits for a diagnosis of osteoporosis on DEXA. However, a greater proportion of those with fractures reported consuming >35 units/week (30% vs. 21%, n.s.) compared to those without. Excessive alcohol use is a major risk factor for osteoporosis in most studies [23] [24] [25] and is one of the three major causes of secondary osteoporosis among men. 17, 18 Previously, two studies in HIV patients have shown a statistically significantly increased risk of fracture among excess alcohol drinkers. 14, 26 There is evidence that at high levels alcohol is directly toxic to osteoblast function, but a considerable proportion of the increased risk of fracture is explained by increased falls risk. To our knowledge, a protective effect of alcohol at low levels on BMD has not been previously shown among HIV-infected patients, but among other populations, especially women, regular intake of small quantities of alcohol has shown benefit for bone health. 23, 24 The role of cART in osteoporosis causation remains controversial. 9, 27 Although PI use was implicated in the first meta-analysis of case-control studies, 6 subsequent re-analysis suggested that the adverse effects may be mediated through BMI. 28 The results of the current study, with rigorous adjustment for confounding factors, again suggest a lesser role for cART than that found in the early studies. Comparison of those naı¨ve to cART with those taking cART <3 years and longterm cART users suggested no significant differences between groups. PI use was associated with osteoporosis in univariate but not multivariable analyses and duration since infection appeared a more important factor. It must be borne in mind however that this study was cross-sectional and the methods only applied 'current use' of drug classes. Many of the subjects treated with long-term cART will have been exposed to different drugs in different combinations over variable time periods. Clearly what is required to identify true effects of cART are longer term prospective studies with fracture as the outcome.
It is surprising that BMD was not significantly associated with BMI < 18 kg/m 2 in this study. Low BMI is usually an important determinant of risk of osteoporosis and we would have expected to see a significant relationship. However, this study was powered for the principal outcome measure and as such we calculated that we had only a 44% power to demonstrate a statistically significant relationship of low BMI with BMD.
Hypogonadism is a well-recognized risk factor for osteoporosis among men. 17, 18 Previous work from this centre 29 demonstrated that mean lumbar spine BMD was significantly lower in hypogonadal versus eugonadal patients (p ¼ 0.05). However, the findings of this study did not replicate this. There are several possible explanations for this. Firstly, there is increasing agreement amongst endocrinologists that measurement of serum testosterone as performed in most laboratories is relatively inaccurate. 30 Plasma concentrations of testosterone vary depending upon age, other disease, time of day and other circulating steroid levels. Moreover, only 1-3% of testosterone is not bound to plasma proteins so that it is unclear if free testosterone is the most clinically useful measure. Therefore, our lack of association may have arisen as a result of the assay used in this study. Our study found an unexpectedly relatively low proportion of subjects (1%) who were hypogonadal on baseline free testosterone assay. Certainly, a larger number of subjects (n ¼ 10, 12%) had a preexisting diagnosis of hypogonadism and were being treated with supplementation and therefore the recent measurement of testosterone may have reflected adequate treatment. Recently, however, other studies have failed to show an association between hypogonadism and low BMD in HIV-infected populations. 31 Observing 1325 HIV-infected men, Rochira and colleagues 31 found low testosterone in 16%. It was mainly associated with low or normal serum luteinising hormone and the main predictor was visceral adipose tissue (lipodystrophy) and BMI. It is currently therefore unclear what proportion of HIV-infected patients are truly hypogonadal and further work is needed to understand the vital relationships between body mass, body fat distribution and HIV-associated low bone mass.
In conclusion, this study has shown a high prevalence of low BMD among an HIV-infected male cohort and a 3.5-fold increased risk of self-reported fracture amongst those with osteoporosis on DEXA. The principal risk factor for osteoporosis was time since diagnosis of HIV infection >13 years and neither cART use per se nor any particular cART class were strongly implicated.
